Review of the novelties presented at the 28th congress of the european committee for treatment and research in multiple sclerosis (ECTRIMS) (III);Revisión de las novedades presentadas en el XXVIII congreso del comité europeo para el tratamiento e investigación en esclerosis múltiple (ECTRIMS) (III)

Revista de Neurologia

Volumn 57, Issue 7, 2013, Pages 317-329

  Fernández, Óscar ^a   Arnal García, Carmen ^b   Arroyo González, Rafael ^c   Brieva, Lluís ^d   Calles Hernández, M Carmen ^e   Casanova Estruch, Bonaventura ^f   Comabella, Manuel ^g   de las Heras, Virginia ^g   García Merino, Juan A ^h   Hernández Pérez, Miguel A ⁱ   Izquierdo, Guillermo ^j   Matas, Elisabet ^k   Meca Lallana, José E ^l   Mendibe Bilbao, María del Mar ^m   Muñoz García, Delicias ⁿ   Olascoaga, Javier ^o   Oreja Guevara, Celia ^p   Prieto, José M ^q   Ramió Torrentà, Lluís ^r   Rodríguez Antigüedad, Alfredo ^s   Saiz, Albert ^t   Téllez, Nieves ^u   Villar, Luisa M ^v   Tintoré, Mar ^a   more..

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁿ HOSPITAL DE CRUCES   (Spain)

^o HOSPITAL XERAL CÍES   (Spain)

^p HOSPITAL DONOSTIA   (Spain)

^q HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^r HOSPITAL JOSEP TRUETA   (Spain)

^s HOSPITAL DE BASURTO   (Spain)

^t HOSPITAL CLÍNIC   (Spain)

^u HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^v HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Cannabinoids; Cell therapy; Glatiramer acetate; Laquinimod; Multiple sclerosis

Indexed keywords

DACLIZUMAB; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LAQUINIMOD; NATALIZUMAB; PONESIMOD; SECUKINUMAB; TERIFLUNOMIDE;

CELL THERAPY; CONGRESS OF THE EUROPEAN COMMITTEE; HUMAN; MULTIPLE SCLEROSIS; PROFESSIONAL STANDARD; REMYELINIZATION; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; EUROPE; HUMANS; IMMUNOTHERAPY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; PHARMACOVIGILANCE; THERAPIES, INVESTIGATIONAL;

EID: 84885589335     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5707.2013277     Document Type: Review

References (49)

1. Confavreux C. Standpoint of the neurologist. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
2. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
3. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
4. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129: 595-605.
5. Leray E, Yaouanq J, Le PE, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-13.
6. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-29.
7. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006; 108: 327-32.
8. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77: 1246-52.
9. Tutuncu M, Tang J, Abou Zeid N, Kale N, Crusan D, Atkinson E, et al. Do all patients with multiple sclerosis ultimately develop progressive MS? 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
10. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008; 70: 1134-40.
11. Garattini S, Bertele V, Banzi R. Placebo? No thanks, it might be bad for me! Eur J Clin Pharmacol 2013; 69: 711-4.
12. Wolinsky J. Surrogate outcomes for immunomodulation and neuroprotection. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
13. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010; 75: 302-9.
14. Liguori M, Meier DS, Hildenbrand P, Healy BC, Chitnis T, Baruch NF, et al. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 1125-31.
15. Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bull N Y U Hosp Jt Dis 2008; 66: 150-4.
16. Sormani M. From natural to treated history-standpoint of the mehodologist. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
17. Lublin F. Outcomes in MS clinical trials. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
18. Spelman T, Pellegrini F, Zhang A, Hyde R, Pace A, Arnold R, et al. Comparison of natalizumab and interferon-beta/ glatiramer efficacy using propensity-matched registry data. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
19. Khan O, Bao F, Shah M, Caon C, Tselis A, Bailey R, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci 2012; 312: 7-12.
20. Lindsey J, Scott T, Lynch S, Cofield S, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord 2012; 1: 81-6.
21. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40 mg administered 3 times a week compared to placebo. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
22. Wegner C, Stadelmann C, Pfortner R, Raymond E, Feigelson S, Alon R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010; 227: 133-43.
23. Comi G. Oral laquinimod reduced relapse rate and delayed progression of disability in Allegro, a placebo-controlled phase III trial for RRMS. Late-Breaking Science Session of the 63rd Annual Meeting of the American Academy of Neurology. Honolulu, Hawaii, April 2011.
24. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Effect of BG-12 on contrast-enhancing lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 2012; 18: 314-21.
25. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-97.
26. Kappos L, Comi G, Confavreux C, Freedman M, Miller A, Olsson T, et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study. 8th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
27. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-303.
28. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E, et al. Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
29. Olsson T, Boster A, Fernandez O, Freedman M, Pozzilli C, Bach D, et al. Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
30. Havrdova E, Belova A, Goloborodko A, Tisserant A, Jones I, Garren H, et al. Positive proof of concept of AIN457, an antibody against interleukin-17A, in relapsing-remitting multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
31. Romme-Christensen J, Ratzer R, Bornsen L, Garde E, Lyksborg M, Siebner H, et al. Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage -results of a phase 2A proof-of-concept study. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
32. Fox R, Kappos L, Cree B, Kaufman M, Jeffery D, Weinstock- Guttman B, et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. 5th Joint Triennial Congress of ECTRIMS and ACTRIMS. Amsterdam, The Netherlands, October 2011.
33. Papeix C, Vukusic S, Passante N, Ionescu I, Frangoulis B, Stankoff B, et al. Natalizumab discontinuation in clinical practice: a systematic observational study from the national TYSEDMUS cohort of 577 multiple sclerosis patients treated with natalizumab in France. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
34. Selmaj K. Antigen specific therapy of MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
35. Fernandez O, Arnal-Garcia C, Arroyo-Gonzalez R, Brieva LL, Calles-Hernandez MC, Casanova-Estruch B, et al. Revision de las novedades presentadas en el XXVIII Congreso del Comite Europeo para el Tratamiento e Investigacion en Esclerosis Multiple (ECTRIMS) (II). Rev Neurol 2013; 57: 269-81.
36. Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006; 13: 887-95.
37. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62: 865-70.
38. Uccelli A. Autologous mesenchymal stem cells for the treatment of MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
39. Karussis D, Vaknin-Dembinsky A. Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting. Expert Rev Clin Immunol 2010; 6: 347-52.
40. Burman J, Fagius J, Totterman T, Fransson M, Mangsbo S, Loskog A. Immune reconstitution after autologous haematopoietic stem cell transplantation for aggressive relapsingremitting MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
41. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007; 130: 1254-62.
42. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006; 66: 1935-7.
43. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebocontrolled, parallel-group, enriched-design study of nabiximols (Sativex ®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-31.
44. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-31.
45. Leocani L, Formenti A, Nuara A, Rossi P, Martinelli-Boneschi F, Zangen A, et al. Walking improvement after deep rTMS with H-coil associated with rehabilitation in patients with progressive multiple sclerosis: a randomised, controlled, double-blind study. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
46. Tognoni G. Pharmaco-epidemiology: methodological aspects. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
47. Vermersch P. Epidemiology of natalizumab-associated PML and IRIS in MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
48. Richert N, Bloomgren G, Cadavid D, Dong-Si T, Richman S, Ticho B. Imaging findings for PML in natalizumab-treated MS patients. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
49. Fernandez O, Arnal-Garcia C, Arroyo-Gonzalez R, Brieva LL, Calles-Hernandez MC, Casanova-Estruch B, et al. Revision de las novedades presentadas en el XXVIII Congreso del Comite Europeo para el Tratamiento e Investigacion en Esclerosis Multiple (ECTRIMS) (I). Rev Neurol 2013; 57: 217-29.